Head and Neck Cancer

PD 10 - H&N 2 - Head and Neck Poster Discussion

1081 - A Phase II Study of Radiation Therapy Deintensification for HPV-Associated Oropharyngeal Carcinomas: Long-Term Oncologic and Toxicity Results

Tuesday, October 23
1:00 PM - 1:06 PM
Location: Room 217 A/B

A Phase II Study of Radiation Therapy Deintensification for HPV-Associated Oropharyngeal Carcinomas: Long-Term Oncologic and Toxicity Results
M. P. Deek1, L. Sloan2, A. Blackford3, R. Abrams3, E. Cecil3, H. Starmer3, C. Fakhry4, C. G. Gourin4, H. Kang3, K. Webster3, J. Richmon5, C. Chung6, W. Koch3, A. P. Kiess7, G. Sanguineti3, T. R. McNutt7, A. A. Forastiere8, and H. Quon7; 1Johns Hopkins Medicine, Baltimore, MD, 2The Johns Hopkins Hospital, Department of Radiation Oncology and Molecular Radiation Sciences, Baltimore, MD, 3Johns Hopkins Hospital, Baltimore, MD, 4Department of Otolaryngology, Head and Neck Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, 5John Hopkins Hospital, Baltimore, MD, 6Moffitt Cancer Center, Tampa, FL, 7Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, 8Johns Hopkins University School of Medicine, Baltimore, MD

Purpose/Objective(s): Human papilloma virus (HPV) – associated oropharyngeal squamous cell carcinomas (OPSCC) have a favorable prognosis. When treated with radiation therapy (RT), reducing the risk of late complications while maintaining oncologic efficacy are important goals. Our group hypothesized that our deintensification protocol would limit the 2-year grade ≥3 late CTCAE toxicities to <15% while maintaining local-regional tumor control >85%. We sought to report the mature results of our study.

Materials/Methods: From 2010 to 2015, we prospectively enrolled patients on a phase II trial of AJCC (version VII) stage I-IV HPV-OPSCC treated with RT or concurrent chemoradiation (CRT) with weekly cisplatin, excluding T4 tumors. Patients with T1-2 N0-1 tumours were eligible for treatment with RT alone to 70 Gy to the primary and nodal gross tumor volume (GTV). All remaining patients received CRT with the primary GTV reduced to 63 Gy where it overlapped the pharyngeal constrictor muscles, larynx or the parotid glands and 70 Gy to the nodal GTV. Patients were prospectively evaluated for the primary composite endpoint of 2-year local-regional tumour control and late CTCAE toxicities.

Results: 59 patients were enrolled with a median follow up of 49.3 months (19.1-87 months). Median age was 59 years old (39 - 80). 17 (28.8%), 30 (50.9%), and 11 (18.6%) patients had T1, T2, and T3 tumors, respectively. The majority of patients had advanced nodal disease (N2a – 5, N2b – 29, N2c – 13, N3 – 4) and stage (IVA – 47, IVB – 4). At last follow up, one patient had local recurrence (at 8 months), two patients had regional recurrences (at 3.5 and 21.3 months), three patients developed distant metastasis, and one patient developed synchronous regional and distant failure. The cumulative 2-year incidence of local failure was 1.5%, region failure was 3.5% and local-regional failure 5.0%. 54 (91.5%) patients had at least two-year follow-up toxicity data. At two years, 32 (59.3%) patients reported no dysphagia, 21 (38.9%) reported grade 1 dysphagia, and 1 (1.9%) reported grade 3 dysphagia; 33 (61%) and 15 (27.8%) reported grade 1 or 2 xerostomia and none reported grade 3 xerostomia. M. D. Anderson Dysphagia Inventory (MDADI) scores at 2 years were available for 45 (76.2%) patients. Median MDADI score for the population was 64 (range 41-76). Sydney swallow questionnaire scores were available for 54 patients at a median of 48.8 months with a median SSQ score of 118.8 (range 15.2-808.9) suggesting normal patient-reported physiologic swallow function (0-234).

Conclusion: RT de-intensification was safely conducted in HPV+OPSCC with a favorable toxicity profile, limited to a single grade 3 toxicity. While successfully achieving the primary study endpoint, the MDADI evaluation suggests that further deintensification efforts are needed along with more sensitive toxicity measures beyond CTCAE grading for future study endpoints.

Author Disclosure: M.P. Deek: None. L. Sloan: None. A. Blackford: None. H. Starmer: None. C.G. Gourin: chair, head and neck surgery/ oncology cmte; AAOHNSF. council member; AHNS. H. Kang: None. C. Chung: Research Grant; Boehringer Ingelheim. Advisory Board; Novartis. G. Sanguineti: None. T.R. McNutt: Research Grant; Elekta Oncology Systems, Philips Radiation Oncology Systems, Toshiba. Patent/License Fees/Copyright; Accuray-Tomotherapy, Sun Nuclear. President Elect; AAPM-MAC. A.A. Forastiere: None.

Send Email for Matthew Deek


Assets

1081 - A Phase II Study of Radiation Therapy Deintensification for HPV-Associated Oropharyngeal Carcinomas: Long-Term Oncologic and Toxicity Results



Attendees who have favorited this

Please enter your access key

The asset you are trying to access is locked. Please enter your access key to unlock.

Send Email for A Phase II Study of Radiation Therapy Deintensification for HPV-Associated Oropharyngeal Carcinomas: Long-Term Oncologic and Toxicity Results